PMID- 35004790
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220111
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single 
      Center.
PG  - 812010
LID - 10.3389/fmed.2021.812010 [doi]
LID - 812010
AB  - The temporal association had been reported between vaccination and exacerbation 
      of psoriasis, and episodes of psoriasis flare-up have recently been attributed to 
      COVID-19 vaccines. We recruited 32 unimmunized controls and 51 vaccinated 
      psoriasis patients, 49 of whom were under biological therapy, with regular clinic 
      visits receiving a total of 63 shots of vaccines, including 30 doses of Moderna 
      mRNA-1273 and 33 doses of AstraZeneca-Oxford AZD1222. Fifteen episodes of 
      exacerbation attacked within 9.3 +/- 4.3 days, which is higher than two episodes in 
      the control group (p = 0.047). The mean post-vaccination severity of the 
      worsening episodes increased from PASI 3.1 to 8.0 (p < 0.001). Three patients 
      showed morphologic change from chronic plaque-type to guttate psoriasis. 
      Deterioration of psoriasis following COVID-19 vaccination was not associated with 
      age, sex, disease duration, psoriatic arthritis, family history of psoriasis, 
      history of erythroderma, current biologics use, comorbidities, vaccine types, 
      human leukocyte antigen (HLA)-C genotypes, baseline PASI nor pre-vaccination 
      PASI. For those who received two doses of vaccination, all but one patient 
      aggravated after the first shot but not the second. The mechanism of psoriasis 
      exacerbation in immunized individuals is unclear, but Th17 cells induced by 
      COVID-19 vaccines may play a role. In the pandemic era, psoriasis patients and 
      physicians should acknowledge the possibility of fluctuation of disease activity 
      when vaccinated against COVID-19. Nevertheless, compared to a treatable 
      dermatologic disease with rapid resolution of exacerbation, psoriasis patients 
      who do not have contraindications to vaccination should benefit from COVID-19 
      vaccines in the prevention of severe COVID-19 infection and fatality.
CI  - Copyright (c) 2021 Huang and Tsai.
FAU - Huang, Yi-Wei
AU  - Huang YW
AD  - Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
FAU - Tsai, Tsen-Fang
AU  - Tsai TF
AD  - Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.
AD  - Department of Dermatology, College of Medicine, National Taiwan University, 
      Taipei, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20211223
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8733241
OTO - NOTNLM
OT  - COVID-19
OT  - HLA
OT  - Th17
OT  - biologics
OT  - exacerbation
OT  - human leukocyte antigen
OT  - psoriasis
OT  - vaccine
COIS- T-FT has conducted clinical trials or received honoraria for serving as a 
      consultant for Abbvie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, 
      Eli-Lilly, Galderma, Janssen-Cilag, Merck Sharp and Dohme, Novartis International 
      AG, Pfizer Inc., and UCB Pharma. However, none of the above has direct conflict 
      regarding this manuscript. The remaining author declares that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2022/01/11 06:00
MHDA- 2022/01/11 06:01
PMCR- 2021/12/23
CRDT- 2022/01/10 09:26
PHST- 2021/11/09 00:00 [received]
PHST- 2021/12/06 00:00 [accepted]
PHST- 2022/01/10 09:26 [entrez]
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/01/11 06:01 [medline]
PHST- 2021/12/23 00:00 [pmc-release]
AID - 10.3389/fmed.2021.812010 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Dec 23;8:812010. doi: 10.3389/fmed.2021.812010. 
      eCollection 2021.